Comparative Pharmacology
Head-to-head clinical analysis: CALCIPARINE versus HEPARIN SODIUM 20 000 UNITS IN DEXTROSE 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALCIPARINE versus HEPARIN SODIUM 20 000 UNITS IN DEXTROSE 5.
CALCIPARINE vs HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unfractionated heparin (UFH) potentiates antithrombin III (ATIII) activity, leading to inhibition of factor Xa and thrombin (factor IIa). It also binds to heparin cofactor II, inhibits platelet aggregation, and increases vascular permeability.
Heparin sodium binds to antithrombin III, causing a conformational change that accelerates the inactivation of thrombin and factor Xa, and to a lesser extent factors IXa, XIa, and XIIa, thereby inhibiting coagulation. It also inhibits platelet aggregation and prolongs clotting times.
5000 IU subcutaneously twice daily for prophylaxis; 5000 IU intravenous bolus followed by 800-1000 IU/hour continuous intravenous infusion for treatment.
Adults: Initial IV bolus 80 units/kg, then continuous IV infusion at 18 units/kg/hour. For therapeutic anticoagulation, adjust to target aPTT 1.5-2.5 times control. Dosing per institutional nomogram.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5 hours (subcutaneous) after a 5000 IU dose. With therapeutic doses (e.g., 15,000 IU/24h), half-life may prolong to 2-3 hours. Clinical context: Half-life is dose-dependent and increases with heparin clearance saturation.
Terminal half-life 1.5 hours (range 1-3 hours) for therapeutic doses; dose-dependent, with higher doses prolonging half-life; half-life prolonged in hepatic or renal impairment.
Primarily renal, with 40-60% of the dose excreted unchanged in urine. Minor biliary/fecal elimination (<10%).
Renal: 50-60% as unchanged drug via glomerular filtration; hepatic metabolism (desulfation) accounts for minor clearance; fecal elimination negligible (<1%).
Category C
Category A/B
Anticoagulant
Anticoagulant